HOME >> MEDICINE >> NEWS
FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy

TITUSVILLE, NJ, June 30, 2005 -- The U.S. Food and Drug Administration (FDA) yesterday approved a new use for TOPAMAX (topiramate) Tablets and TOPAMAX (topiramate capsules) Sprinkle Capsules as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than two seizures in the three months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

"Anti-epilepsy medications, or neuromodulators, are selected based on seizure type; however, the specific seizure type may not always be obvious at the time of diagnosis," said Tracy Glauser, M.D., director of the Comprehensive Epilepsy Center at the Cincinnati Childrens Hospital. "A treatment like TOPAMAX, which provides coverage for both partial-onset and primarily generalized tonic-clonic seizures, offers doctors an option in situations where differentiating between these seizure types is difficult."

Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain that temporarily disrupt normal brain function. Seizures are classified as "generalized," originating in both sides of the brain simultaneously, or "partial-onset," starting in one area of the brain.

In a double-blind clinical trial, 470 patients with partial-onset or primary generalized tonic-clonic seizures were randomized to treatment with 50 mg or 400 mg/day of TOPAMAX. The primary efficacy assessment was a group comparison of time to first seizure during the double-blind phase of the study. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the 400 mg/day group over the 50mg/day group. The recommended dose for monotherapy in patients 10 years of age and older is 400 mg/da
'"/>

Contact: Debbie Harvey
dharvey@golinharris.com
312-729-4374
Golin/Harris International
30-Jun-2005


Page: 1 2 3

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
4. VCR -- FDA approves home discharge for US patients
5. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
6. FDA approves Vectibix to treat patients with metastatic colorectal cancer
7. 5,000 rare diseases need drugs, but Europe only approves a handful each year
8. FDA approves room temperature storage of ZLB Behrings Helixate FS
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Majority of herb users dont follow evidence-based indications, researchers find

Post Your Comments:
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 ... Sunset Plaza Dental announces that they are now ... restorative and other dental treatments. At consultations, patients ... them. Questions regarding what certain treatments can achieve ... be covered during this initial appointment. If treatments ...
(Date:5/22/2015)... Boca Raton, FL (PRWEB) May 22, 2015 ... organization which provides vascular, electrocardiogram (EKG), echocardiogram and ... of David Sempier, a highly respected All American National ... a multi-sport athlete, I find the high level of ... to both the athlete and their athletic trainers, this ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... In efforts to offer full and ... particular muscles stretches has been a large focus over ... now complete, Chunk Fitness envisions a mid-June launch of ... and released at a later point in time. The ... http://www.chunkfitness.com/stretches . , About the Company: Chunk Fitness was ...
(Date:5/21/2015)... York (PRWEB) May 21, 2015 World ... patented products, launches the Troll Motor Guide, a boat ... of boating. , "The recreational boating industry has reached ... Cooper, CEO and Creative Director of World Patent ... record numbers and predicts continued steady growth of seven ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "Arthroscopy ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose ... size the world market for Arthroscopy Devices. ... trends impacting the market for these products. ...
(Date:5/21/2015)... NEW YORK , 21. Mai ... (NASDAQ: DPRX ), ein Unternehmen ... sich auf die Entwicklung und Vermarktung ... Forschungszusammenarbeit konzentriert, kündigte heute eine wissenschaftliche ... der Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 ...
(Date:5/21/2015)... , May 21, 2015 Research and Markets ... addition of the "Global Next Generation Sequencing ... The global next generation sequencing market to ... period 2014-2019 This report covers the ... global next generation sequencing market for the period ...
Breaking Medicine Technology:Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Global Next Generation Sequencing Market 2015-2019 2
Cached News: